UCB moves to buy Candid Therapeutics for up to $2.2B

UCB said on May 3 it signed a definitive agreement to acquire Candid Therapeutics for up to $2.2 billion, including $2.0 billion upfront and up to $200 million in milestone payments. The deal gives UCB Candid’s lead asset, cizutamig, a BCMAxCD3 bispecific T-cell engager being studied across more than 10 autoimmune indications, plus a broader multispecific pipeline aimed at depleting pathogenic B-cell populations. UCB said the transaction is expected to close in late Q2 or early Q3 2026, subject to antitrust clearance and other customary conditions. (ucb.com)

Why it matters: For veterinary professionals, this is another signal that large biopharma companies are putting real money behind “immune reset” approaches rather than chronic immune suppression alone. While the pipeline is human-focused, the science around targeted B-cell and plasma-cell depletion, cytokine-release mitigation, and bispecific antibody engineering is relevant to anyone tracking where immunology is heading, including future translational work that could eventually shape companion animal therapeutics. UCB is also building this as a platform play, not a one-off asset purchase, following its March 2026 licensing deal with Antengene for the CD19/CD3 T-cell engager ATG-201. (ucb.com)

What to watch: Watch for deal closing in mid-2026, the fate of Candid’s previously announced Rallybio merger, and whether UCB accelerates cizutamig into phase 2 studies in indications such as myasthenia gravis and interstitial lung disease tied to rheumatologic disease. (pharmexec.com)